Skip to main content
Equibles

Avidity Partners Management LP

Position in AKTS — Aktis Oncology, Inc.

CIK 1791827 DALLAS, TX
Back to AKTS Full portfolio

Position in AKTS

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$15,605,766
+$7,223,121 QoQ
Shares Held
484,200
+3.3% QoQ
Ownership
0.871%
of shares outstanding
% of Portfolio
2.50%
of 13F equity value
Holder Rank
#18
of 114 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in AKTS Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Avidity Partners Management LP holds $524,784,316 across 27 Biotechnology names. AKTS ranks #6 (3.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 DNTH
Dianthus Therapeutics, Inc. /DE/
 2,104,184 $205,115,856
2 CGON
CG Oncology, Inc.
 1,398,948 $99,395,255
3 ORKA
Oruka Therapeutics, Inc.
 760,424 $72,369,552
4 JBIO
Jade Biosciences, Inc.
 1,700,708 $37,789,731
5 ELVN
Enliven Therapeutics, Inc.
 550,000 $27,912,500
6 AKTS
Aktis Oncology, Inc.
This page 		484,200 $15,605,766
7 PVLA
Palvella Therapeutics, Inc.
 70,000 $10,697,400
8 IMUX
Immunic, Inc.
 669,941 $10,296,993

All Filings in AKTS

Export CSV
2 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $15,605,766 484,200
2026-03-31 $8,382,645 468,566